基于网络药理学技术挖掘蒲地蓝消炎口服液的活性组分与作用机制

Investigation of active components and mechanism of Pudilan Xiaoyan Oral Liquid based on network pharmacology

基于网络药理学技术,挖掘蒲地蓝消炎口服液有效组分/成分,并对其潜在作用靶点、机制进行网络数据分析。通过活性成分筛选,蛋白相互作用分析,通路注释等技术对其活性成分、潜在靶点进一步优选,明确蒲地蓝消炎口服液的药效物质基础及其作用机制。通过该技术筛选出蒲地蓝消炎口服液中41种活性成分,主要包括菊苣酸、绿原酸、汉黄芩苷、芦丁、紫堇灵、七叶内酯等在内的16种生物碱类组分、13种有机酸类组分、11种黄酮类组分和1种香豆素组分。另外筛选出腮腺炎相应靶点6个、扁桃体炎相应靶点48个,咽喉炎相应靶点22个,共涉及疾病信号通路22条,包括与炎症密切相关的4条通路,其中IL-17 signaling pathway的degree最大,可能与炎症疾病最为密切相关。通过数据挖掘,该研究初步探索蒲地蓝消炎口服液的主要活性组分/成分,并研究其治疗相关疾病的药效物质基础及其关键的作用机制,为蒲地蓝消炎口服液的深度研究和产品提升奠定基础。

To investigate the active components/ingredients of Pudilan Xiaoyan Oral Liquid based on the network pharmacology technology,and analyze the network data of its potential targets and mechanisms.The active ingredient screening,protein interaction analysis and pathway annotation were used to further optimize its active components and potential targets,and clarify the pharmacodynamic substance basis and mechanism of Pudilan Xiaoyan Oral Liquid.Through this technique,we screened out 41 active ingredients in Pudilan Xiaoyan Oral Liquid,mainly including 16 alkaloid components,13 organic acid components,11 flavonoid components and 1 coumarin component such as chicoric acid,chlorogenic acid,oroxindin,rutin,corynoline,and esculetin.In addition,6 targets for parotitis,48 targets for tonsillitis,and 22 targets for pharyngitis were screened.A total of 22 disease signaling pathways are involved,including 4 pathways closely related to inflammation.The IL-17 signaling pathway had the highest D(degree)value and may be most closely related to inflammatory diseases.Through network data excavating,we initially explored the main active components/ingredients of Pudilan Xiaoyan Oral Liquid,clarified the pharmacodynamic basis of Pudilan Xiaoyan Oral Liquid treatment-related diseases and its key mechanism of action in this study,hoping to provide a theoretical basis for clinical research,and at the same time,lay the foundation for deep research and promotion of Pudilan Xiaoyan Oral Liquid product.